Telix Pharmaceuticals (TLX) meets FY 2025 revenue guidance and advances Illucix in China

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited filed a Form 6-K highlighting two key updates first released on the Australian Securities Exchange. The company reports that the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix, marking an important regulatory step for this product in China. Telix also states that it achieved its FY 2025 guidance with US$804 million (A$1.2 billion) in revenue and is accelerating growth with the launch of Gozellix. Together, these disclosures point to strong recent commercial performance and progress in expanding the company’s product portfolio and geographic reach.

Positive

• FY 2025 guidance achieved with US$804M (A$1.2B) revenue, indicating substantial commercial scale and delivery on stated financial targets.
• Chinese NMPA acceptance of the New Drug Application for Illucix, advancing the product toward potential approval in a major new market.
• Launch of Gozellix described as accelerating growth, suggesting an expanding product portfolio contributing to revenue.

Negative

• None.

Insights

Biopharma & Earnings Analyst

Telix hits FY 2025 revenue target and advances Illucix in China.

Telix Pharmaceuticals reports FY 2025 revenue of US$804M (approximately A$1.2B), explicitly stating that this achieves its full-year guidance. Hitting stated revenue guidance suggests execution in line with prior expectations and indicates that the commercial portfolio is generating substantial sales.

Separately, the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix. NDA acceptance is a formal step that allows the Chinese regulator to review the product for potential marketing authorization, which could expand Illucix access into a large new market if later approved.

The company also highlights the launch of Gozellix as helping to accelerate growth, signaling that additional products are beginning to contribute alongside Illucix. Future disclosures in company filings may provide more detail on how revenue is split across regions and products and on the regulatory review progress for Illucix in China.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On January 20, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited (the “Company”) filed an announcement with the Australian Securities Exchange (“ASX”) titled “Chinese NMPA Accepts New Drug Application for Illucix,” which is attached to this Form 6-K as Exhibit 99.1 (“First ASX Release”).

On January 20, 2026 (Melbourne, Australia), the Company filed an announcement with the ASX titled “Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch,” which is attached to this Form 6-K as Exhibit 99.2 (“Second ASX Release”).

99.1 First ASX Release

99.2

                                  Second ASX Release

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: January 20, 2026	By:	/s/ Genevieve Ryan
		Name: Genevieve Ryan
		Title: Company Secretary

FAQ

What key updates does Telix Pharmaceuticals (TLX) report in this Form 6-K?

The Form 6-K notes two ASX announcements: acceptance of a New Drug Application for Illucix by the Chinese National Medical Products Administration and confirmation that Telix achieved its FY 2025 revenue guidance with US$804M (A$1.2B), alongside the launch of Gozellix.

How much FY 2025 revenue did Telix Pharmaceuticals (TLX) report?

Telix states that it achieved its FY 2025 guidance with US$804 million (A$1.2 billion) in revenue, as disclosed in an announcement titled “Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch.”

What is the regulatory milestone for Illucix mentioned by Telix (TLX)?

Telix reports that the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix, allowing the product to enter formal regulatory review in China.

What is Gozellix and how is it described by Telix Pharmaceuticals (TLX)?

In the referenced ASX announcement, Telix describes the launch of Gozellix as helping to accelerate growth, indicating it is a commercial product contributing to the company’s expansion.

Does this Telix (TLX) Form 6-K include full financial statements?

The Form 6-K itself primarily references ASX announcements, including that FY 2025 revenue was US$804M (A$1.2B). Detailed financial statements, if any, are contained in the attached ASX release rather than in the brief Form 6-K text.

Which markets are highlighted for Telix Pharmaceuticals (TLX) in this update?

The update highlights regulatory progress in China through NDA acceptance for Illucix and references strong FY 2025 revenue and growth acceleration with the launch of Gozellix, reflecting Telix’s broader commercial footprint.